NO20090667L - Tartratsalt av (7S)-7-[(5-fluor-2-metyl-benzyl)oksy]-2-[(2R)-2-metylpiperazin-1-yl]-6,7-dihydro-5H-syklopenta[b] pyridin - Google Patents
Tartratsalt av (7S)-7-[(5-fluor-2-metyl-benzyl)oksy]-2-[(2R)-2-metylpiperazin-1-yl]-6,7-dihydro-5H-syklopenta[b] pyridinInfo
- Publication number
- NO20090667L NO20090667L NO20090667A NO20090667A NO20090667L NO 20090667 L NO20090667 L NO 20090667L NO 20090667 A NO20090667 A NO 20090667A NO 20090667 A NO20090667 A NO 20090667A NO 20090667 L NO20090667 L NO 20090667L
- Authority
- NO
- Norway
- Prior art keywords
- tartrate salt
- cyclopenta
- dihydro
- oxy
- fluoro
- Prior art date
Links
- 150000003892 tartrate salts Chemical class 0.000 title abstract 4
- ZAZVLBZIEZHJFV-BEFAXECRSA-N (7s)-7-[(5-fluoro-2-methylphenyl)methoxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine Chemical compound C[C@@H]1CNCCN1C1=CC=C(CC[C@@H]2OCC=3C(=CC=C(F)C=3)C)C2=N1 ZAZVLBZIEZHJFV-BEFAXECRSA-N 0.000 title 1
- 230000007278 cognition impairment Effects 0.000 abstract 2
- 201000000980 schizophrenia Diseases 0.000 abstract 2
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 abstract 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 abstract 1
- -1 5-fluoro-2-methyl-benzyl Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83089006P | 2006-07-14 | 2006-07-14 | |
PCT/IB2007/002025 WO2008010073A1 (fr) | 2006-07-14 | 2007-07-09 | Sel de tartrate de (7s)-7-[(5-fluoro-2-méthyl-benzyl)oxy]-2-[(2r)-2-méthylpipérazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090667L true NO20090667L (no) | 2009-02-11 |
Family
ID=38542082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090667A NO20090667L (no) | 2006-07-14 | 2009-02-11 | Tartratsalt av (7S)-7-[(5-fluor-2-metyl-benzyl)oksy]-2-[(2R)-2-metylpiperazin-1-yl]-6,7-dihydro-5H-syklopenta[b] pyridin |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100004259A1 (fr) |
EP (1) | EP2044029B1 (fr) |
JP (1) | JP4312243B2 (fr) |
KR (1) | KR20090029299A (fr) |
CN (1) | CN101506172A (fr) |
AR (1) | AR062068A1 (fr) |
AT (1) | ATE496894T1 (fr) |
AU (1) | AU2007274710A1 (fr) |
CA (1) | CA2657640A1 (fr) |
DE (1) | DE602007012254D1 (fr) |
IL (1) | IL196417A0 (fr) |
MX (1) | MX2009000508A (fr) |
NO (1) | NO20090667L (fr) |
TW (1) | TW200821293A (fr) |
WO (1) | WO2008010073A1 (fr) |
ZA (1) | ZA200901051B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009063992A1 (fr) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | Dérivé de pyridine condensé et son utilisation |
JP5124308B2 (ja) | 2008-02-26 | 2013-01-23 | 株式会社リコー | トナー、該トナーを用いた現像剤、トナー入り容器、プロセスカートリッジ、及び画像形成方法 |
WO2010079605A1 (fr) * | 2009-01-09 | 2010-07-15 | 東レ・ファインケミカル株式会社 | Procédé de production de la 1-benzyl-3-aminopyrrolidine de pureté élevée |
TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α7活化劑之用途 |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
CN105073054B (zh) | 2013-01-16 | 2018-07-10 | 史赛克公司 | 指示视线误差的导航系统和方法 |
US9993273B2 (en) | 2013-01-16 | 2018-06-12 | Mako Surgical Corp. | Bone plate and tracking device using a bone plate for attaching to a patient's anatomy |
US10095785B2 (en) * | 2013-09-30 | 2018-10-09 | Sonos, Inc. | Audio content search in a media playback system |
WO2015066344A1 (fr) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation |
WO2016069036A1 (fr) * | 2014-11-01 | 2016-05-06 | Hewlett Packard Enterprise Development Lp | Mise à jour dynamique de métadonnées |
US10537395B2 (en) | 2016-05-26 | 2020-01-21 | MAKO Surgical Group | Navigation tracker with kinematic connector assembly |
PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
CA3047354A1 (fr) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Systeme therapeutique transdermique contenant de l'asenapine et un polysiloxane ou un polyisobutylene |
CA3067938A1 (fr) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | Systeme therapeutique transdermique contenant de l'asenapine et un polymere hybride acrylique de type silicone |
UA124793C2 (uk) * | 2017-07-11 | 2021-11-17 | Берінґер Інґельгайм Інтернаціональ Ґмбг | Заміщені похідні ксантину |
CA3101420A1 (fr) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Systeme therapeutique transdermique contenant de l'asenapine |
EP3669876A1 (fr) * | 2018-12-18 | 2020-06-24 | Aelis Farma | 3béta- (benzyloxy)-17alpha-méthyl-pregn-5-en-20-one pour une utilisation dans le traitement de troubles cognitifs |
WO2023248222A1 (fr) * | 2022-06-21 | 2023-12-28 | Technion Research & Development Foundation Limited | Agents modulateurs du récepteur 5-ht2c pour le traitement de troubles neurodégénératifs, mentaux, cognitifs et auto-immuns |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4985352A (en) * | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
EP0361489A3 (fr) * | 1988-09-30 | 1991-06-12 | Chugai Seiyaku Kabushiki Kaisha | Composés de 3,4-diaminoquinoline et de pyridine |
DE4326151A1 (de) * | 1993-08-04 | 1995-02-09 | Hoechst Ag | Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen |
TW270114B (fr) * | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
TW334423B (en) * | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
US5698766A (en) * | 1995-04-05 | 1997-12-16 | The Regents Of The University Of California | Transgenic animal model for testing drugs for treating eating disorders and epilepsy |
US6875769B2 (en) * | 1996-05-23 | 2005-04-05 | Pfizer Inc. | Substituted6,6-hetero-bicyclicderivatives |
US6040448A (en) * | 1997-10-24 | 2000-03-21 | Neurogen Corporation | Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands |
NZ506465A (en) * | 1998-02-26 | 2003-08-29 | Akzo Nobel Nv | Derivatives of azetidine and pyrrolidine |
GB9819033D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
WO2000012077A1 (fr) * | 1998-09-01 | 2000-03-09 | Bristol-Myers Squibb Company | Inhibiteurs de canaux potassium et leur methode d'utilisation |
GB9819019D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
GB9819035D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
US6465467B1 (en) * | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
EP1250230B1 (fr) * | 2000-01-25 | 2005-04-27 | Koenig & Bauer Aktiengesellschaft | Machine a imprimer sur feuilles dotee d'un cylindre serigraphique |
TW527590B (en) * | 2000-04-25 | 2003-04-11 | Matsushita Electric Ind Co Ltd | Compact disk, and the manufacturing method of the same, and the manufacturing device of compact disk |
SE0004245D0 (sv) * | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
DE60216747T2 (de) * | 2001-04-09 | 2007-10-04 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten |
US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
EP1557411B1 (fr) * | 2002-07-12 | 2012-10-17 | Astellas Pharma Inc. | Derive de n-phenyl-(2r,5s)dimethylpiperazine |
EP1613322A4 (fr) * | 2003-04-11 | 2008-08-13 | Taigen Biotechnology Co Ltd | Composes a base d'aminoquinoline |
US7101881B2 (en) * | 2003-06-11 | 2006-09-05 | Pfizer Inc | Tetrahydroquinolines |
US20070015771A1 (en) * | 2004-07-29 | 2007-01-18 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
BRPI0609268A2 (pt) * | 2005-03-31 | 2010-03-09 | Pfizer Prod Inc | derivados de ciclopentapiridina e tetraidroquinolina |
-
2007
- 2007-07-09 KR KR1020097002844A patent/KR20090029299A/ko not_active Application Discontinuation
- 2007-07-09 MX MX2009000508A patent/MX2009000508A/es unknown
- 2007-07-09 CA CA002657640A patent/CA2657640A1/fr not_active Abandoned
- 2007-07-09 WO PCT/IB2007/002025 patent/WO2008010073A1/fr active Application Filing
- 2007-07-09 DE DE602007012254T patent/DE602007012254D1/de active Active
- 2007-07-09 AU AU2007274710A patent/AU2007274710A1/en not_active Abandoned
- 2007-07-09 AT AT07735013T patent/ATE496894T1/de not_active IP Right Cessation
- 2007-07-09 EP EP07735013A patent/EP2044029B1/fr not_active Not-in-force
- 2007-07-09 CN CNA2007800316816A patent/CN101506172A/zh active Pending
- 2007-07-12 JP JP2007182717A patent/JP4312243B2/ja not_active Expired - Fee Related
- 2007-07-13 TW TW096125659A patent/TW200821293A/zh unknown
- 2007-07-13 AR ARP070103136A patent/AR062068A1/es not_active Application Discontinuation
-
2008
- 2008-01-24 US US12/373,774 patent/US20100004259A1/en not_active Abandoned
-
2009
- 2009-01-08 IL IL196417A patent/IL196417A0/en unknown
- 2009-02-11 NO NO20090667A patent/NO20090667L/no not_active Application Discontinuation
- 2009-02-13 ZA ZA200901051A patent/ZA200901051B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP4312243B2 (ja) | 2009-08-12 |
DE602007012254D1 (de) | 2011-03-10 |
AR062068A1 (es) | 2008-10-15 |
MX2009000508A (es) | 2009-01-27 |
EP2044029B1 (fr) | 2011-01-26 |
JP2008044931A (ja) | 2008-02-28 |
WO2008010073A8 (fr) | 2009-03-05 |
CN101506172A (zh) | 2009-08-12 |
WO2008010073A1 (fr) | 2008-01-24 |
AU2007274710A1 (en) | 2008-01-24 |
TW200821293A (en) | 2008-05-16 |
ATE496894T1 (de) | 2011-02-15 |
CA2657640A1 (fr) | 2008-01-24 |
ZA200901051B (en) | 2010-01-27 |
KR20090029299A (ko) | 2009-03-20 |
EP2044029A1 (fr) | 2009-04-08 |
US20100004259A1 (en) | 2010-01-07 |
IL196417A0 (en) | 2009-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090667L (no) | Tartratsalt av (7S)-7-[(5-fluor-2-metyl-benzyl)oksy]-2-[(2R)-2-metylpiperazin-1-yl]-6,7-dihydro-5H-syklopenta[b] pyridin | |
MX2010008638A (es) | Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas. | |
MX2009010728A (es) | Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora. | |
EA200700617A1 (ru) | Новые пиридиновые производные и их применение в качестве позитивных аллостерических модуляторов mglur2-рецепторов | |
SG195085A1 (en) | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors | |
MX2009005908A (es) | Derivados novedosos de diaza-espiro-piridinona sustituidos para usarse en las enfermedades mediadas por la hormona concentradora de melanina 1. | |
NZ595625A (en) | Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators | |
EA201000332A1 (ru) | 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны | |
NZ598269A (en) | Aryl sulphone derivatives as calcium channel blockers | |
TN2009000199A1 (en) | Heteromonocyclic compound and use thereof | |
MA31442B1 (fr) | 3-(imidazolyl)-pyrazolo [3,4-b]pyridines | |
EA201000331A1 (ru) | 1',3-двузамещенные 4-(арил-х-фенил)-1h-пиридин-2-оны | |
EA201000314A1 (ru) | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны | |
TN2011000379A1 (en) | [1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors | |
EP2826472A3 (fr) | Composés d'activation de la télomérase et leur utilisation | |
MY147320A (en) | Process for the preparation of piperazinyl and diazepanyl benzamide derivatives | |
MX2010010597A (es) | Procesos para la preparacion de derivados de dioxina benzofusionados. | |
MA33242B1 (fr) | Composes pour le traitement de troubles metaboliques | |
NO20080393L (no) | Halogenerte pyrazolo [1,5-A] pyrimidiner, fremgangsmater, anvendelse som GABA-A reseptorligander, sammensetninger og intermediater | |
MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
MX2008002366A (es) | Antagonistas triciclicos fusionados de mglur1 como agentes terapeuticos. | |
NO20072972L (no) | Terapeutiske pyrazolo[3,4-B]pyridiner og indazoler | |
WO2008011484A3 (fr) | Désensibilisateurs nicotiniques et procédés pour les sélectionner, les tester et les utiliser | |
WO2008057575A3 (fr) | Nouvelles arylbicyclo[3.1.0]hexylamines et procédés et compositions en vue de leur préparation et de leur utilisation | |
TW200740826A (en) | Fused tricyclic mGluR1 antagonists as therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |